University of Montréal
Blood cancer type
acute myeloid leukemia (AML)
The molecular landscape of leukemia-specific antigens
The goal of our project is to develop therapeutic vaccines against acute myeloid leukemia (AML). We therefore need to discover molecules that are present only on leukemic cells and that can be recognized by the immune system. To this end, we have developed a disruptive method based on next generation sequencing, mass spectrometry and bioinformatics. Using this proteogenomic method, we have discovered mouse leukemia antigens that elicit strong protective immune response and lead to elimination of leukemic cells. Using our unique method, we now looking to discover leukemia antigens that can be used as therapeutic AML vaccines.
Preventive vaccines against various pathogens represent the most cost-effective way to save lives. We believe that almost anybody would wholeheartedly trade a course of chemotherapy for a vaccine.